Key Points
- COO Ryan Fukushima sold 5,000 shares on Dec. 1 at an average of $75.72 for a total of $378,600, leaving him with 153,808 shares (a 3.15% reduction in his stake).
- The Dec. 1 transaction continues a recent pattern of insider selling — including sales on Nov. 18 (10,099 shares), Nov. 3 (5,000) and Oct. 6 (5,000) — suggesting sustained dispositions over the past months.
- Tempus shares trade around $74.91 (52-week range $31.36–$104.32); the company beat quarterly EPS estimates and reported revenue up 84.7% year-over-year, but remains unprofitable and carries a consensus analyst rating of "Hold" with an average target of $81.17.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David Epstein sold 250 shares of the firm's stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $75.55, for a total value of $18,887.50. Following the sale, the director directly owned 26,421 shares of the company's stock, valued at $1,996,106.55. The trade was a 0.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Tempus AI Trading Up 0.5%
NASDAQ TEM traded up $0.36 during trading hours on Thursday, reaching $75.27. The company had a trading volume of 430,868 shares, compared to its average volume of 10,939,252. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $104.32. The stock has a market capitalization of $13.39 billion, a P/E ratio of -62.80 and a beta of 4.99. The stock has a 50-day moving average of $82.14 and a 200 day moving average of $72.81. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million for the quarter, compared to analyst estimates of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business's revenue for the quarter was up 84.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.46) EPS. As a group, research analysts anticipate that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tempus AI
Several hedge funds and other institutional investors have recently made changes to their positions in TEM. Victory Capital Management Inc. increased its stake in shares of Tempus AI by 1.5% during the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company's stock worth $894,000 after buying an additional 162 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Tempus AI by 29.5% in the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company's stock valued at $59,000 after buying an additional 167 shares in the last quarter. US Bancorp DE grew its position in shares of Tempus AI by 6.6% in the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company's stock valued at $230,000 after buying an additional 176 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Tempus AI by 0.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company's stock valued at $2,145,000 after buying an additional 226 shares during the last quarter. Finally, SeaCrest Wealth Management LLC raised its stake in Tempus AI by 3.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company's stock worth $524,000 after acquiring an additional 229 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company's stock.
Wall Street Analyst Weigh In
TEM has been the subject of a number of research reports. BTIG Research lifted their price objective on Tempus AI from $96.00 to $105.00 and gave the company a "buy" rating in a research note on Tuesday, November 25th. Needham & Company LLC lifted their target price on Tempus AI from $70.00 to $100.00 and gave the company a "buy" rating in a research report on Wednesday, November 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tempus AI in a research note on Wednesday, October 8th. Guggenheim increased their price target on shares of Tempus AI from $80.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, September 26th. Finally, Morgan Stanley lifted their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the company an "overweight" rating in a report on Monday. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $81.17.
View Our Latest Stock Analysis on Tempus AI
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
